tumor protein p53 inducible nuclear protein 1Genealiases: SIP · TP53DINP1 · TP53INP1A · TP53INP1B · Teap · p53DINP1
Q-omics provides the consensus-scored TP53INP1 profile across patient tissues and cancer cell-line models. TP53INP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TP53INP1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TP53INP1 RNA expression shows 20,996 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where TP53INP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53INP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53INP1 survival associations across molecular data types. TP53INP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53INP1 RNA expression–survival associations across cancer types. High TP53INP1 expression shows unfavorable associations in UVM and KICH, but favorable associations in HNSC, BLCA, MESO and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TP53INP1 RNA expression.
This table summarizes TP53INP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TP53INP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53INP1 shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP, BRCA, THCA and HNSC. The KIRC box plot shows higher TP53INP1 RNA expression in tumor versus normal tissue (log2 FC = +1.005, t-test p < 0.001).
This table shows molecular features associated with TP53INP1 in patient tissues and cancer cell lines. In patient samples, TP53INP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53INP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
